目的 探討地西他濱聯(lián)合HAG方案治療骨髓增生異常綜合征的臨床療效及其安全性評價。方法 選擇2014年8月-2016年8月在南陽市第二人民醫(yī)院治療的骨髓增生異常綜合征患者56例，隨機分為兩組，對照組26例，接受HAG化療，觀察組30例患者，接受地西他濱聯(lián)合HAG化療，比較兩組患者的臨床療效以及不良反應的發(fā)生情況。結果 第1個療程結束后，對照組患者的總緩解率為26.9%，觀察組為30.0%，雖然觀察組的緩解率較高，但是統(tǒng)計分析差異并不顯著。兩個療程結束后，觀察組的總緩解率為83.3%，顯著高于對照組患者的57.7%，差異有統(tǒng)計學意義（P<0.05）。觀察組發(fā)生25例次不良反應，顯著低于對照組（43例次），差異有統(tǒng)計學意義（P<0.05）。結論 地西他濱輔助治療可以顯著改善HAG化療治療骨髓增生異常綜合征的臨床療效，降低化療期間不良反應的發(fā)生率，提高患者的生活質量，值得臨床推廣應用。

Objective To explore the curative effect and safety of decitabine combined with HAG for patients with myelodysplastic syndromes. Methods Fifty-six patients with myelodysplastic syndromes in Nanyang Second General Hospital from August 2014 to August 2016 were divided randomly into control group (n=26, accepted HAG chemotherapy) and study group (n=30, adopted decitabine combined with HAG) to compare the clinical curative and the incidence of adverse reactions between two groups. Results After a course of treatment, the total remission of control group was 26.9%, and study group was 30%, and difference was no significance between two groups. After two courses of treatment, the total remission of study group (83.3%) was higher significantly than those of control group (57.7%). The case of adverse reactions of study group (25 cases) was lower than control group significantly (P<0.05). Conclusions Decitabine assisted HAG chemotherapy could improve the clinical curative effect remarkably for patients myelodysplastic syndromes, which deserved popularization in clinic duo to the decreasing incidence of adverse reactions and the well quality of life.